吉非替尼联合化疗对比化疗在EGFR突变阳性且一线吉非替尼耐药的非小细胞肺癌中的总生存与生物标志物分析(IMPRESS)
IMPRESS研究纳入265例EGFR突变阳性、一线吉非替尼进展后的晚期非小细胞肺癌患者,随机接受吉非替尼或安慰剂联合顺铂+培美曲塞。中位OS 13.4 vs 19.5个月),该劣化在T790M突变阳性患者中显著(HR 1.49,95%CI 1.02-2.21),T790M阴性者未达统计学显著(HR 1.15,95%CI 0.68-1.94)。
要点
- 一线吉非替尼进展后,继续吉非替尼联合化疗较安慰剂联合化疗显著劣化OS(HR 1.44,中位OS 13.4 vs 19.5个月)。
- T790M突变阳性患者中继续吉非替尼联合化疗的OS劣化显著(HR 1.49,95%CI 1.02-2.21)。
- T790M突变阴性患者中OS差异未达统计学显著(HR 1.15,95%CI 0.68-1.94)。
核心结论
- 最终OS数据支持此前PFS结果,足以警告医生在开始化疗时不应在影像学疾病进展后继续使用第一代EGFR酪氨酸激酶抑制剂。
- 血浆生物标志物分析提示该效应可能由T790M阳性状态驱动。
研究设计与样本
- IMPRESS为多中心随机研究,比较吉非替尼联合化疗与安慰剂联合化疗在EGFR突变阳性晚期非小细胞肺癌一线吉非替尼进展后的疗效。
- 共265例患者随机分配,总数据成熟度为66%。
- 患者随机接受吉非替尼250 mg或安慰剂,联合顺铂75 mg/m2加培美曲塞500 mg/m2(化疗最多6个周期)。
- EGFR突变状态通过血浆循环游离肿瘤DNA样本检测(微珠、乳化、扩增和磁力数字聚合酶链反应 assay,等位基因分数分析)。
主要发现
- 在T790M突变阳性血浆样本患者中,OS劣化具有统计学显著性(HR 1.49;95%CI 1.02-2.21)。
- 在T790M突变阴性患者中,OS差异未达到统计学显著性(HR 1.15;95%CI 0.68-1.94)。
临床怎么用
- 在开始化疗时,不应在影像学疾病进展后继续使用第一代EGFR酪氨酸激酶抑制剂。
- 血浆T790M状态可能有助于识别继续吉非替尼联合化疗带来OS劣化的患者。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The Iressa Mutation-Positive Multicentre Treatment Beyond ProgRESsion Study (IMPRESS) compared the continuation of gefitinib plus chemotherapy with placebo plus chemotherapy in patients with epidermal growth factor receptor ( EGFR) mutation-positive advanced non-small-cell lung cancer with progression (Response Evaluation Criteria in Solid Tumors 1.1) after first-line gefitinib. Primary results indicated no difference between treatments in terms of progression-free survival (PFS). The current analysis presents final, mature, overall survival (OS) data, together with exploratory analyses that examined whether specific biomarkers, including T790M mutation status, were able to differentiate a relative treatment effect. Patients and Methods Patients were randomly assigned to gefitinib 250 mg or placebo, in addition to cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2 (maximum of six cycles of chemotherapy). EGFR mutation status was determined from plasma-derived circulating free tumor-derived DNA samples (beads, emulsification, amplification, and magnetics digital polymerase chain reaction assay, allelic fraction analysis). Results A total of 265 patients with non-small-cell lung cancer were randomly assigned, and overall data maturity was 66%. Continuation of gefitinib plus cisplatin and pemetrexed was detrimental to OS when compared with placebo plus cisplatin and pemetrexed (hazard ratio [HR], 1.44; 95% CI, 1.07 to 1.94; P = .016; median OS, 13.4 v 19.5 months). The detriment was statistically significant in patients with T790M mutation-positive plasma samples (HR, 1.49; 95% CI, 1.02 to 2.21), whereas statistical significance was not reached in T790M mutation-negative patients (HR, 1.15; 95% CI, 0.68 to 1.94). PFS in T790M mutation-positive patients was similar between treatments, and the difference observed in T790M mutation-negative patients did not reach statistical significance (HR, 0.67; 95% CI, 0.43 to 1.03; P = .0745). Conclusion Final OS data from IMPRESS are supportive of earlier PFS results and are sufficient to warn physicians against the continuation of treatment with first-generation EGFR tyrosine kinase inhibitors beyond radiologic disease progression when chemotherapy is initiated. Plasma biomarker analyses suggest that this effect may be driven by T790M-positive status.
引用
- Mok TSK, Kim SW, Wu YL, et al. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017. PMID: 28968167. doi:10.1200/JCO.2017.73.9250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。